IS2233B - Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær - Google Patents

Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær

Info

Publication number
IS2233B
IS2233B IS5666A IS5666A IS2233B IS 2233 B IS2233 B IS 2233B IS 5666 A IS5666 A IS 5666A IS 5666 A IS5666 A IS 5666A IS 2233 B IS2233 B IS 2233B
Authority
IS
Iceland
Prior art keywords
gamma
processes
making
acid derivatives
aminobutyric acid
Prior art date
Application number
IS5666A
Other languages
English (en)
Other versions
IS5666A (is
Inventor
Aomatsu Akira
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2233(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS5666A publication Critical patent/IS5666A/is
Publication of IS2233B publication Critical patent/IS2233B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)
IS5666A 1998-05-15 2000-10-16 Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær IS2233B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15
PCT/US1999/010190 WO1999059573A1 (en) 1998-05-15 1999-05-10 Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same

Publications (2)

Publication Number Publication Date
IS5666A IS5666A (is) 2000-10-16
IS2233B true IS2233B (is) 2007-04-15

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5666A IS2233B (is) 1998-05-15 2000-10-16 Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær

Country Status (37)

Country Link
US (1) US7309719B1 (is)
EP (1) EP1077692B1 (is)
JP (1) JP4612923B2 (is)
KR (1) KR100602047B1 (is)
CN (1) CN1303991C (is)
AR (1) AR020323A1 (is)
AT (1) ATE271864T1 (is)
AU (1) AU768277B2 (is)
BR (1) BR9910508B1 (is)
CA (1) CA2327285C (is)
CO (1) CO5021224A1 (is)
CR (1) CR6026A (is)
CU (1) CU23253B7 (is)
DE (1) DE69918977T2 (is)
DK (1) DK1077692T3 (is)
EG (1) EG26803A (is)
ES (1) ES2221385T3 (is)
GT (1) GT199900069A (is)
HK (1) HK1036586A1 (is)
HN (1) HN1999000072A (is)
HU (1) HU228771B1 (is)
ID (1) ID27724A (is)
IL (2) IL139298A0 (is)
IS (1) IS2233B (is)
MY (1) MY157878A (is)
NO (1) NO328959B1 (is)
NZ (1) NZ508015A (is)
PA (1) PA8472801A1 (is)
PE (1) PE20000556A1 (is)
PL (1) PL204921B1 (is)
PT (1) PT1077692E (is)
SI (1) SI1077692T1 (is)
SV (1) SV1999000064A (is)
TW (1) TWI243054B (is)
UY (1) UY25512A1 (is)
WO (1) WO1999059573A1 (is)
ZA (1) ZA200006484B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
DE60101476T2 (de) * 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
ATE334656T1 (de) * 2001-05-25 2006-08-15 Warner Lambert Co Flüssige pharmazeutische zusammensetzung
WO2005074895A1 (en) * 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
CA2565095A1 (en) * 2004-05-17 2005-12-08 William S. Brusilow Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
MX364974B (es) 2009-05-19 2019-05-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine
US10561602B2 (en) 2015-05-26 2020-02-18 Isa Odidi Controlled extended release pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
CN113164423A (zh) 2018-10-04 2021-07-23 美德阿利克斯株式会社 用非水溶剂稳定化的制剂
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
EP4049679A4 (en) 2019-10-25 2023-11-01 Kyoto University PREVENTIVE OR THERAPEUTIC AGAINST TAUOPATHY
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
ES2165857T3 (es) * 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
WO1998003167A1 (en) * 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity

Also Published As

Publication number Publication date
CO5021224A1 (es) 2001-03-27
HK1036586A1 (en) 2002-01-11
ES2221385T3 (es) 2004-12-16
GT199900069A (es) 2000-11-04
CN1301155A (zh) 2001-06-27
WO1999059573A9 (en) 2000-05-04
ZA200006484B (en) 2002-02-11
KR100602047B1 (ko) 2006-07-19
MY157878A (en) 2016-07-29
HN1999000072A (es) 2000-06-05
PL344218A1 (en) 2001-10-08
CA2327285C (en) 2005-06-14
NO20005768L (no) 2000-11-14
KR20010043611A (ko) 2001-05-25
CR6026A (es) 2008-08-26
NO20005768D0 (no) 2000-11-14
SI1077692T1 (en) 2004-10-31
PT1077692E (pt) 2004-12-31
WO1999059573A1 (en) 1999-11-25
EG26803A (en) 2014-09-21
DK1077692T3 (da) 2004-12-06
HUP0102022A2 (hu) 2001-11-28
DE69918977T2 (de) 2005-07-28
TWI243054B (en) 2005-11-11
EP1077692B1 (en) 2004-07-28
BR9910508B1 (pt) 2012-01-24
SV1999000064A (es) 2000-03-31
AR020323A1 (es) 2002-05-08
ATE271864T1 (de) 2004-08-15
HUP0102022A3 (en) 2002-11-28
ID27724A (id) 2001-04-26
PE20000556A1 (es) 2000-08-10
AU4073599A (en) 1999-12-06
PL204921B1 (pl) 2010-02-26
EP1077692A1 (en) 2001-02-28
CN1303991C (zh) 2007-03-14
HU228771B1 (en) 2013-05-28
IL139298A0 (en) 2001-11-25
CU23253B7 (es) 2007-12-17
JP2000034226A (ja) 2000-02-02
IL139298A (en) 2009-07-20
NO328959B1 (no) 2010-06-28
US7309719B1 (en) 2007-12-18
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
CA2327285A1 (en) 1999-11-25
JP4612923B2 (ja) 2011-01-12
BR9910508A (pt) 2001-01-02
IS5666A (is) 2000-10-16
DE69918977D1 (de) 2004-09-02
AU768277B2 (en) 2003-12-04
UY25512A1 (es) 1999-07-19

Similar Documents

Publication Publication Date Title
IS5666A (is) Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær
IS6197A (is) Aðferð og búnaður til að koma lyfjablöndum á úðaform
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
NO20004741D0 (no) Farmasøytiske blandinger for forlenget peptidfrigjøring og fremstillingsmetode
DK1041879T3 (da) Desinfektionsmiddel og fremstillingsmetode
IS1991B (is) Lyfjaþrýstiúðasamsetningar og aðferð til framleiðslu þeirra
DK0876332T3 (da) Phenyleddikesyrederivater, fremgangsmåde og mellemprodukter til deres fremstilling og midler indeholdende disse
IS6724A (is) Aðferð til framleiðslu á N-arýl-anþranilískum sýrum og afleiðum þeirra
DK0985697T3 (da) Oxiranderivater og fremgangsmåde til fremstilling deraf
NO20025664L (no) Fremgangsmate for fremstilling av cyklopropylkarboksylsyreestere og derivater
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
IS5647A (is) Fastefnalyfjablöndur sem í eru gamma-amínósmjörsýruafleiður, og ferli til að smíða slíkar blöndur
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
DK0725567T3 (da) Forbedrede tyggegummisammensætninger og fremgangsmåder til fremstilling deraf
DK0889880T3 (da) Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO331215B1 (no) Kit av deler og farmasoytiske formuleringer
PL353721A1 (en) Citric acid eters and method of obtaining them
IL139884A0 (en) N-substituted derivatives of 5-oximinobarbituric acid
NO20011610D0 (no) Blanding og fremgangsmåte for fjerning av sure gasser
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
NO20011611D0 (no) Blanding og fremgangsmåte for fjerning av sure gasser
DK1131052T3 (da) Vaginalt indgivelige progesteron-holdige tabletter og fremgangsmåde til fremstilling deraf
IS5809A (is) Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar